期刊文献+

马晓燕教授从肝脾肾论治肾性骨病临床经验撷要 被引量:10

The clinical experience of Professor Ma Xiaoyan on the treatment of renal osteopathy from Liver, Spleen and Kidney
下载PDF
导出
摘要 马晓燕教授从事慢性肾衰并发症肾性骨病的临床研究多年,经验丰富。笔者有幸在吾师处学习,现将吾师对此病的治疗经验总结如下。据吾师之临床经验总结认为肾性骨病之病因有内因和外因之分。内因以肾元亏虚为主,外因责之于反复外感、七情内伤、饮食失节、劳倦过度而伤肾损脾或水肿、淋证、消渴、眩晕等久病迁延、失治而损伤肾脏。吾师针对此病的病因病机特点,结合大量临床实践,总结形成了滋补肝肾,健脾泄浊,化瘀排毒的治疗方法,扶正祛邪,标本兼顾。辨证治疗,配合适当的饮食及生活调护,临床疗效颇佳。 My mentor Professor Ma Xiaoyan has been engaged in the clinical research on Chronic Kidney Disease-Mineral and Bone Disorde(CKD-MBD)for many years and has accumulated rich clinical experience.I have the honor to follow Professor Ma and sum up her experience on the treatment of the disease as follows.Professor Ma holds that the etiology of CKD-MBD could be divided into the internal and the external factors.The internal factor mainly includes kidney deficiency,the external factors include repeatedly colds,emotional injuries,improper diet,and overstrain damage of the spleen and kidney,or edema,stranguria,diabetes,chronic illness which is persistent for a long time and causes kidney damage.According to the etiology and pathogenesis of the disease and combined with a large number of clinical cases,Professor Ma sums up the therapeutic method of nourishing the liver and kidney,tonifying spleen and relieving turbidity,removing blood stasis and detoxifying.Strengthening the body resistance to eliminate pathogenic factors,dialectical treatment combined with proper diet and life nursing could achieve significant clinical curative effect.
出处 《中医临床研究》 2018年第18期5-7,共3页 Clinical Journal Of Chinese Medicine
关键词 肾性骨病 中医药疗法 肝脾肾论治 名医经验 马晓燕 Renal osteopathy Chinese medicine Treatment of liver spleen and kidney Experience of famous doctors Ma Xiaoyan
  • 相关文献

参考文献4

二级参考文献35

  • 1周育平,安成,胡元会,张振鹏.心肾综合征患者临床特征及中医证候特点分析[J].时珍国医国药,2010,21(12):3362-3363. 被引量:22
  • 2Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis[J]. Nephrol Dial Transplant, 2009, 24 (12): 3794-3799.
  • 3Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis [J]. Clin J Am Soc Nephrol, 2008, 3 (4) : 1125-1130.
  • 4Hutchison A J, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6 month, randomized, comparative trial versus calcium carbonate [J]. Nephron Clin Pract, 2005, 100(1) : 8-19.
  • 5Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment [J]. Nephron Clin Pract, 2008, 110(1) : 15-23.
  • 6Hayashi M, Tsuchiya Y, Itaya Y, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial[J]. Nephrol Dial Transplant, 2004, 19 (8): 2067-2073.
  • 7Sprague M, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J]. Kidney Int, 2003, 63 (4): 1483-1490.
  • 8Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism:a sequential comparison [J]. Am J Kidney Dis, 2001, 37 (3): 532-543.
  • 9Lippuner K, Perrelet R, Casez JP, et al. 1,25- (OH) 2-16ene- 23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect[J]. Horm Res, 2004, 61 (1) : 7-16.
  • 10Brown AJ, Ritter CS, Weiskopf AS, et al. Isolation and identification of lalpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion [J]. J Cell Biochem, 2005, 96 (3) : 569-578.

共引文献69

同被引文献145

引证文献10

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部